# ClinicalTrials.gov record NCT02748369

> PeptideScanner retained ClinicalTrials.gov record NCT02748369 at 2026-07-30T19:36:31.410Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was glucagon.

- Evidence object: `story:clinicaltrials-gov-nct02748369-glucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-08-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02748369-glucagon/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02748369-glucagon-v1.json
- Content SHA-256: `e773c1cd080218c82d63e0197bf79afc916501f945d20d2763b7b54274f75582`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02748369 ([`ctg-observation-nct02748369-2022-08-03-9448612fe869`](#source-ctg-observation-nct02748369-2022-08-03-9448612fe869))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02748369 at 2026-07-30T19:36:31.410Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was glucagon. ([`ctg-observation-nct02748369-2022-08-03-9448612fe869`](#source-ctg-observation-nct02748369-2022-08-03-9448612fe869))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02748369 at 2026-07-30T19:36:31.410Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was glucagon. ([`ctg-observation-nct02748369-2022-08-03-9448612fe869`](#source-ctg-observation-nct02748369-2022-08-03-9448612fe869))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02748369-2022-08-03-9448612fe869`](#source-ctg-observation-nct02748369-2022-08-03-9448612fe869))

## Sources

<a id="source-ctg-observation-nct02748369-2022-08-03-9448612fe869"></a>
- **ClinicalTrials.gov record NCT02748369 · retained source version 2022-08-03:9448612fe869f671ed89f6fde109f1406e18d0eaa9b8c81275bb152216588f31** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02748369) (`ctg-observation-nct02748369-2022-08-03-9448612fe869`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02748369." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02748369-glucagon-v1.json SHA-256: e773c1cd080218c82d63e0197bf79afc916501f945d20d2763b7b54274f75582.